title: Therapeutic vaccine using a monoclonal antibody against a 70-kDa glycoprotein in mice infected with highly virulent Sporothrix schenckii and Sporothrix brasiliensis.
abstract: Sporotrichosis is a chronic granulomatous mycosis caused by the dimorphic fungi that comprise the Sporothrix complex. The latter are widely distributed in nature, developing a saprophytic mycelial form on plant debris and soil. Formerly, the S. schenckii species was thought to be the only species capable of causing sporotrichosis. However, in recent years, the existence of a group of highly genotypically and phenotypically variable species has been reported as etiologic agents of this mycosis. Recently, it has become important to study aspects such as virulence and the immune response against key members of the Sporothrix complex and to observe the presence of glycoprotein (gp) 70 and efficacy of the P6E7 monoclonal antibody against more virulent strains. The data presented here demonstrate that the strain isolated from a case of feline sporotrichosis, that is, strain 5110 (American Type Culture Collection MYA-4823) is the most virulent and the only one able to secrete gp70. This glycoprotein is apparently an important factor in the virulence of Sporothrix spp. because treatment with MAb P6E7 resulted in the reduction of fungal burden in the analyzed organs. Additional studies of the role of gp70 in modulating the immune response of the host are needed to understand the pathology of sporotrichosis.
authors.affiliation: Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, Brazil.
authors.forename: José Roberto Fogaça
authors.initials: JR
authors.lastname: de Almeida
authors.affiliation: Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil.
authors.forename: Gilberto Hideo
authors.initials: GH
authors.lastname: Kaihami
authors.affiliation: Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, Brazil.
authors.forename: Grasielle Pereira
authors.initials: GP
authors.lastname: Jannuzzi
authors.affiliation: Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, Brazil sandroal@usp.br.
authors.forename: Sandro Rogerio
authors.initials: SR
authors.lastname: de Almeida
mesh_terms: D000825:Animal Structures / Q000382:microbiology; D000818:Animals; D000908:Antibodies, Fungal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000276:immunology*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D006023:Glycoproteins / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D008807:Mice, Inbred BALB C; D013175:Sporothrix / Q000276:immunology*; D013174:Sporotrichosis / Q000628:therapy*; D016896:Treatment Outcome; D037521:Virulence Factors / Q000276:immunology
chemical_list: D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D000946:Antigens, Fungal; D006023:Glycoproteins; D037521:Virulence Factors
keywords: Sporothrix; monoclonal antibody; sporotrichosis; therapeutic vaccine; virulence